Related Experiment Video
Updated: Jul 16, 2026
Production and Testing of Antimicrobial Peptides and Their Mimics
Published on: April 10, 2026
Parallel evaluation of antimicrobial peptides derived from the synthetic PAF26 and the human LL37
Belén López-García1, Wimal Ubhayasekera, Richard L Gallo
1Departmento de Ciencia de los Alimentos, Instituto de Agroquímica y Tecnología de Alimentos, CSIC, Valencia, Spain. lopezb@iata.csic.es
Abstract:
The antimicrobial hexapeptide PAF26 was de novo designed towards phytopathogenic fungi of agricultural importance. To analyze its clinical potential, the activity of PAF26 has been determined against several microorganisms of clinical relevance including Staphylococcus, Candida, and several dermatophytes. For comparison purposes, the peptides KR20 and KI26 derived from the human cathelicidin LL37 were selected and fungal pathogens of agronomic relevance were included. PAF26 has similar antimicrobial activity in vitro compared to KR20 despite their different lengths and amino acid compositions. Moreover, neither peptide is lytic to human erythrocytes or keratinocytes. The hybrid peptide PAF26:KR20 showed better antimicrobial properties than the original peptides against most of the pathogens tested. The structural properties of PAF26:KR20 compared to related 26-amino acid peptides support the idea that the increment in toxicity correlates with positive charge and hydrophobicity. However, the degree of peptide helicity was not a predictor of antimicrobial activity.
Insights
The novel antimicrobial peptide PAF26 shows potential for clinical use, with activity comparable to existing peptides against various pathogens. A hybrid peptide, PAF26:KR20, demonstrated enhanced antimicrobial properties without causing cell lysis.
Area of Science:
- Antimicrobial Peptides
- Fungal Pathogenesis
- Drug Discovery
Background:
- Phytopathogenic fungi pose significant agricultural threats.
- Antimicrobial peptides (AMPs) are a promising class of therapeutic agents.
- The human cathelicidin LL37 serves as a basis for developing novel AMPs.
Purpose of the Study:
- To evaluate the clinical potential of the de novo designed hexapeptide PAF26.
- To compare the antimicrobial activity of PAF26 with related peptides (KR20, KI26) against clinical and agricultural pathogens.
- To investigate the structural determinants of antimicrobial activity and toxicity in novel peptides.
Main Methods:
- In vitro antimicrobial activity assays against Staphylococcus, Candida, dermatophytes, and phytopathogenic fungi.
- Erythrocyte lysis and keratinocyte cytotoxicity assays to assess safety.
- Structural analysis of peptide properties including charge, hydrophobicity, and helicity.
Main Results:
- PAF26 exhibited comparable in vitro antimicrobial activity to KR20 against a range of microorganisms.
- Neither PAF26 nor KR20 showed lytic activity against human erythrocytes or keratinocytes.
- The hybrid peptide PAF26:KR20 displayed improved antimicrobial efficacy against most tested pathogens.
- Positive charge and hydrophobicity correlated with increased toxicity, while peptide helicity did not predict antimicrobial activity.
Conclusions:
- PAF26 is a promising antimicrobial peptide with potential for clinical applications.
- The hybrid peptide PAF26:KR20 offers enhanced antimicrobial properties and warrants further investigation.
- Peptide design strategies should consider charge and hydrophobicity for optimizing antimicrobial activity and safety.
